TY - JOUR
T1 - Luteolin, a Potent Anticancer Compound
T2 - From Chemistry to Cellular Interactions and Synergetic Perspectives
AU - Singh Tuli, Hardeep
AU - Rath, Prangya
AU - Chauhan, Abhishek
AU - Sak, Katrin
AU - Aggarwal, Diwakar
AU - Choudhary, Renuka
AU - Sharma, Ujjawal
AU - Vashishth, Kanupriya
AU - Sharma, Sheetu
AU - Kumar, Manoj
AU - Yadav, Vikas
AU - Singh, Tejveer
AU - Yerer, Mukerrem Betul
AU - Haque, Shafiul
N1 - Publisher Copyright:
© 2022 by the authors.
PY - 2022/11
Y1 - 2022/11
N2 - Increasing rates of cancer incidence and the toxicity concerns of existing chemotherapeutic agents have intensified the research to explore more alternative routes to combat tumor. Luteolin, a flavone found in numerous fruits, vegetables, and herbs, has exhibited a number of biological activities, such as anticancer and anti-inflammatory. Luteolin inhibits tumor growth by targeting cellular processes such as apoptosis, cell-cycle progression, angiogenesis and migration. Mechanistically, luteolin causes cell death by downregulating Akt, PLK-1, cyclin-B1, cyclin-A, CDC-2, CDK-2, Bcl-2, and Bcl-xL, while upregulating BAX, caspase-3, and p21. It has also been reported to inhibit STAT3 signaling by the suppression of STAT3 activation and enhanced STAT3 protein degradation in various cancer cells. Therefore, extensive studies on the anticancer properties of luteolin reveal its promising role in chemoprevention. The present review describes all the possible cellular interactions of luteolin in cancer, along with its synergistic mode of action and nanodelivery insight.
AB - Increasing rates of cancer incidence and the toxicity concerns of existing chemotherapeutic agents have intensified the research to explore more alternative routes to combat tumor. Luteolin, a flavone found in numerous fruits, vegetables, and herbs, has exhibited a number of biological activities, such as anticancer and anti-inflammatory. Luteolin inhibits tumor growth by targeting cellular processes such as apoptosis, cell-cycle progression, angiogenesis and migration. Mechanistically, luteolin causes cell death by downregulating Akt, PLK-1, cyclin-B1, cyclin-A, CDC-2, CDK-2, Bcl-2, and Bcl-xL, while upregulating BAX, caspase-3, and p21. It has also been reported to inhibit STAT3 signaling by the suppression of STAT3 activation and enhanced STAT3 protein degradation in various cancer cells. Therefore, extensive studies on the anticancer properties of luteolin reveal its promising role in chemoprevention. The present review describes all the possible cellular interactions of luteolin in cancer, along with its synergistic mode of action and nanodelivery insight.
KW - anti-inflammation
KW - anti-metastasis
KW - apoptosis and cell cycle
KW - luteolin
KW - synergistic action
UR - https://www.scopus.com/pages/publications/85141719063
U2 - 10.3390/cancers14215373
DO - 10.3390/cancers14215373
M3 - Artículo de revisión
AN - SCOPUS:85141719063
SN - 2072-6694
VL - 14
JO - Cancers
JF - Cancers
IS - 21
M1 - 5373
ER -